The Science
Our corneal regenerative therapies are the culmination of many years of academic research and collaborations with clinicians to understand how our technologies can be applied to solve medical challenges.
The Benefits
Clinical and veterinary applications for our device are broad, ranging from perforations and ulcers to thinned-corneas and late-stage corneal disease.
Effective early interventions
Treatment using our device can mean that a full keratoplasty or corneal transplant are not subsequently required.
Our product has been designed to fit into the clinical pathway with little adjustment to standard clinical practice.
Improved patient recovery
Recovery from procedures that use our medical device will be faster and more straightforward than full cornea transplant, and complex follow-up should not be required.
Improved Quality of life for patients
Our medical devices will save health services money and lead to better patient outcomes and improved quality of life
Veterinary Device
With increasing pet populations and heightened awareness of pet health, the demand for animal corneal graft surgeries is on the rise.
The veterinary eye care market is large and growing as pet owners increasingly value the place of their pets in their family, and are willing to invest in that care.
Our veterinary device will provide vets with an easy-to-administer alternative to a donor corneal transplant.
Corneal ulcers, most commonly caused by trauma to the eye, are relatively common in horses and dogs, and our device will provide an effective treatment regime to repair damage and restore sight.
Medical Device
As the global population ages, vision impairment is an increasing concern, impacting physical, cognitive and mental health. Corneas are the most frequently transplanted human tissue worldwide, with around 185,000 procedures per annum, however it is estimated that 55% of the world’s population do not have access to donor material.
There is a severe imbalance of access to human cornea tissue between developed and developing countries - with factors such as lower levels of economic and cultural sensitivities impacting the supply of donor corneas.
Che Connon, Co-Founder of Kerato, and Managing Director of BSF Enterprise, commented:
"With 13 million people across the world waiting for a cornea replacement to transform their sight and quality of life, there is a global need for a solution.
Our plan at Kerato is to develop novel medical devices that can accelerate the use of bioengineered corneas as a solution to address medical challenges and inequalities."
